rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

Abstract Background Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas may have pre-existing antibodies from asymptomatic Ebolavirus exposure that might affect response to rVSV-ZEBOV. Therefore, we asses...

Full description

Saved in:
Bibliographic Details
Main Authors: Conall H. Watson, Pierre-Stéphane Gsell, Yper Hall, Anton Camacho, Ximena Riveros, Godwin Enwere, Andrea Vicari, Séverine Danmadji Nadlaou, Alhassane Toure, Ismaila M. Sani, Abdourahamane Diallo, Cece Kolie, Sophie Duraffour, Kékoura Ifono, Andre Maomou, Kassie Dore, Honora A. Djidonou, Aminata Bagayoko, Philos P. Damey, Mabetty Nancy Camara, Fatoumata Battouly Diallo, Fofana Thierno Oumar, Kalidou Toure, Mohamed Lamine Diaby, Lansana Sylla, Doussou Conde, Ibrahima Lansana Kaba, Tom Tipton, Rosalind M. Eggo, Michael Marks, Chrissy H. Roberts, Thomas Strecker, Stephan Günther, Sakoba Keita, W. John Edmunds, Miles W. Carroll, Ana Maria Henao-Restrepo
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Medicine
Subjects:
Ebola virus disease
Ebola
Vaccine
RVSV-ZEBOV
Safety
Immunogenicity
Online Access:https://doi.org/10.1186/s12916-024-03726-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items